Taş, Fuat

Profile Picture
Profile URL
https://hdl.handle.net/20.500.12514/8189
Name Variants
Taş, F.F.
Job Title
Araş. Gör.
Email Address
Main Affiliation
Department of Architecture / Mimarlık Bölümü
Status
Former Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

SDG data is not available
This researcher does not have a Scopus ID.
This researcher does not have a WoS ID.
Scholarly Output

1

Articles

1

Views / Downloads

5/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

WoS h-index

0

Scopus h-index

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

1

Supervised Theses

0

JournalCount
Turkish Archives of Pediatrics1
Current Page: 1 / 1

Scopus Quartile Distribution

Quartile distribution chart data is not available

Competency Cloud

GCRIS Competency Cloud

Filters

20261
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Final Height in Patients with Turner Syndrome Treated with Growth Hormone Therapy
    (AVES, 2026) Aktar Karakaya, A.A.; Unal, E.; Yıldırım, R.; Özalkak, Ş.; Taş, F.F.; Özbek, M.N.; Karakaya, Amine Aktar
    Objective: Turner syndrome (TS) is the most common sex chromosome abnormality in girls. Short stature is the most distinctive feature. This study aimed to evaluate factors affecting final height (FH) in patients with TS who received growth hormone (GH) therapy and achieved their final height (FH). Materials and Methods: About 48 patients with TS who received GH therapy and reached their FH were included and examined retrospectively. Initial height, standard deviation score (SDS), FH, and FH SDS measurements of the patients were obtained. Additionally, factors affecting FH were analyzed. Results: Growth hormone was administered at a dose of 45.6 ± 6.2 (min-max: 34-69) μg/kg/day at a mean age of 11.7 ± 2.9 years. The duration of therapy was 4.3 ± 1.4 years. The mean FH of the patients was 147.80 ± 5.98 cm. About 29.2% (n=14) of the patients reached a height above the thirdpercentile. It was observed that GH therapy was initiated in these patients at a mean age of 10.3 ± 3.1 years; the initial height SDS was better. FH of 45,X and non-45,X cases were similar. Conclusion: In the study, GH therapy that was initiated at an early age in patients with good initial height SDS increased the gain of FH and FH SDS. Therefore, initiating GH therapy at an early age in patients with TS is important for height gain. ∆ Height SDS was better in cases that underwent late pubertal induction. Karyotype did not have a predictive effect on height prognosis. © 2026, AVES. All rights reserved.